DUPIXENT® (dupilumab injection) is now Approved in Canada for the Treatment of Adult and Adolescent Patients (12+) With Eosinophilic Esophagitis
This is the eighth indication for DUPIXENT® in Canada and its first in gastroenterology. MISSISSAUGA, ON — /CNW/ — sanofi-aventis Canada Inc. (Sanofi Canada) is pleased to announce that Health Canada has issued a… Read More




